CardioExchange Archive

November 15th, 2011

After SATURN, What Role for Rosuvastatin? A CardioExchange Panel

CardioExchange Editors, Staff

With the publication and presentation of negative data from the SATURN trial (see our news summary), CardioExchange convened a panel to answer this question: In light of the data from SATURN and the impending arrival of generic atorvastatin, what is the appropriate role of rosuvastatin at this point? Steven E. Nissen, MD (senior author of SATURN) The […]

---

November 15th, 2011

After AIM HIGH, What Future for Niacin? A CardioExchange Panel

CardioExchange Editors, Staff

Steve Nissen, JoAnne Foody, Roger Blumenthal, and AIM HIGH author William Boden weigh in on what patients do and don’t remain good candidates for niacin therapy.

---

November 14th, 2011

PALLAS Intrigue: What Role Remains for Dronedarone?

CardioExchange Editors, Staff

John Mandrola, Eric Prystowsky, and Sanjay Kaul weigh in on PALLAS and the present and future of Multaq.

---

August 22nd, 2011

Panel: Coronary Calcium vs. CRP for Predicting Cardiovascular Events

CardioExchange Editors, Staff

Drs. Paul Ridker and Sanjay Kaul offer their perspectives on a new coronary artery calcium/C-reactive protein study, published in the Lancet, and three of the study authors respond. The study showed that people with low LDL levels and high CRP levels may benefit from CAC scans to identify the folks who are most likely to […]

---

July 25th, 2011

Panel: Will You Prescribe Ticagrelor (Brilinta)?

CardioExchange Editors, Staff

Three experts discuss whether — and with which patients — they will use ticagrelor in clinical practice.

---

July 15th, 2011

Panel: Why Don’t Cardiologists Eat Their OATs?

CardioExchange Editors, Staff

In 2006, the Occluded Artery Trial (OAT) showed no benefit of routine PCI in patients with persistently occluded infarct-related arteries that were identified at least one day after an MI. According to a recent study, led by Judith Hochman, OAT has had minimal impact on clinical practice. We asked Hochman and two other experts why […]

---

July 9th, 2011

Will You Still Use Multaq (Dronedarone)? A CardioExchange Panel

CardioExchange Editors, Staff

Our panel responds to the what the cessation of the PALLAS trial means for dronedarone. Will you still use this drug?

---

July 7th, 2011

Expert Panel: How Often Is PCI Appropriate?

CardioExchange Editors, Staff

The CardioExchange editors have asked a panel of experts to weigh in on a new study published in JAMA. It showed that nearly all the acute percutaneous coronary interventions (PCIs) in the National Cardiovascular Data Registry from June 2009 through September 2010 were warranted, according to “appropriate use criteria” for coronary revascularization. However, the study […]

---

June 23rd, 2011

The Elusive 30-Minute “Door-In to Door-Out” Benchmark for Primary PCI Transfers

CardioExchange Editors, Staff

The editors at CardioExchange have again asked a panel of experts to respond to a clinically important study. This time it was a retrospective cohort study, published in JAMA, of door-in to door-out (DIDO) times for patients with ST-segment-elevation MI who had been admitted to one hospital and then were transferred to another center for […]

---

June 12th, 2011

CardioExchange Panel: Whither High-Dose Simvastatin?

CardioExchange Editors, Staff

Last week, the FDA issued a warning high-dose simvastatin because of the risk of myopathy. CardioExchange got the reactions from a panel we assembled. Whose views do you agree with? What points did our panelists miss? See a similar panel’s reactions the publication of the SHARP Trial here. Given the FDA warning, do you see any role […]

---